Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06527222 · ClinicalTrials.gov registry record · Phase 2
A Study of Ranolazine in ALS
A Phase 2 study of Amyotrophic Lateral Sclerosis, sponsored by Swathy Chandrashekhar, MBBS.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 72
- Enrollment target
- 7
- Study locations
NCT06527222: Recruiting Phase 2 study of Amyotrophic Lateral Sclerosis, sponsored by Swathy Chandrashekhar, MBBS.
NCT06527222 is a Phase 2 study of Amyotrophic Lateral Sclerosis that is actively recruiting participants, run by Swathy Chandrashekhar, MBBS. The registered enrollment target is 72 participants, below the 897-participant average among 102 other Amyotrophic Lateral Sclerosis trials with a reported enrollment target (92% lower). The trial reports 7 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06527222, a Phase 2 study of Amyotrophic Lateral Sclerosis, is actively recruiting participants, sponsored by Swathy Chandrashekhar, MBBS.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 72 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to evaluate safety, effect on cramps, function and quality of life of ranolazine versus placebo for the treatment of ALS.
Primary Outcome
Patient report and medical records will be used to document adverse events and severe adverse events. Adverse events and severe adverse events will be assessed by the investigator and reported as needed for safety.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Ranolazine
Study Locations (7)
Kansas
- University of Kansas Medical Center - Fairway
- University of Kansas Medical Center: Wichita - Wichita
California
- University of California, San Francisco - San Francisco
Florida
- Mayo Clinic Florida - Jacksonville
Missouri
- University of Missouri Health Care - Columbia
Ohio
- The Ohio State University - Columbus
Texas
- National Neuromuscular Research Institute, PLLC. - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2025-04-29 |
| Est. Completion | 2026-05 |
| Phase | Phase 2 |
What NCT06527222 shows while recruiting
NCT06527222 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 72 participants, a relatively small participant target, below the 897-participant average among 102 other Amyotrophic Lateral Sclerosis trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Amyotrophic Lateral Sclerosis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06527222 lists 7 locations in 6 states (Kansas, California, Florida).
Frequently Asked Questions
What is clinical trial NCT06527222 about?
NCT06527222 is a clinical study titled "A Study of Ranolazine in ALS". The purpose of this study is to evaluate safety, effect on cramps, function and quality of life of ranolazine versus placebo for the treatment of ALS.
What is the current status of trial NCT06527222?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 72 participants. The study started on 2025-04-29. Estimated completion is 2026-05.
What conditions does trial NCT06527222 study?
This clinical trial studies the following conditions: Amyotrophic Lateral Sclerosis.
What interventions are being tested in trial NCT06527222?
The interventions under investigation include: Placebo (DRUG), Ranolazine (DRUG).
Who is sponsoring clinical trial NCT06527222?
This trial is sponsored by Swathy Chandrashekhar, MBBS, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06527222 being conducted?
This trial has 7 study locations across California, Florida, Kansas, Missouri, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Amyotrophic Lateral Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06527222's enrollment target sits among peer trials
72 50th of 102 higher than 52 of 102 other Amyotrophic Lateral Sclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Amyotrophic Lateral Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Dazucorilant in Patients With Amyotrophic Lateral Sclerosis
RECRUITING · Phase 2
-
HEALEY ALS Platform Trial - Master Protocol
RECRUITING · Phase 2
-
RAPA-501 Therapy for ALS
RECRUITING · Phase 2
-
Rho Kinase Inhibitor in Amyotrophic Lateral Sclerosis (REAL)
ACTIVE NOT RECRUITING · Phase 2
-
Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS
ACTIVE NOT RECRUITING · Phase 2
-
Intrathecal Autologous Adipose-derived Mesenchymal Stromal Cells for Amyotrophic Lateral Sclerosis (ALS)
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02359253 · 72 participants · NA
Robot Aided Rehabilitation - Intervention
- NCT02962661 · 72 participants · Phase 1
Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines
- NCT03113643 · 72 participants · Phase 1
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- NCT03187535 · 72 participants · NA
Effect of TEAS on PONV After Spinal Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI